LCE3, Human, clone 7
Monoclonal antibody clone 7 recognizes human late cornified envelop (LCE)-3 proteins, with increased affinity for LCE3-, B/D&E.
Read moreMonoclonal antibody clone 7 recognizes human late cornified envelop (LCE)-3 proteins, with increased affinity for LCE3-, B/D&E. Although the exact mechanism is still unknown, psoriasis and psoriatic arthritis are skin diseases with a strong and complex genetic background. The LCE gene cluster and especially cluster 3 is associated with these diseases. Psoriasis is characterized by inflammation, epidermal hyperproliferation and keratinocyte differentiation. Many psoriasis related genes lie within the epidermal differentiation complex (EDC) region. This includes the LCE cluster genes. This cluster encodes genes for stratum corneum proteins. The LCE cluster is divided into 6 groups (LCE1-6) and the LCE3 cluster encompasses five genes (LCE3-, A/B/C/D/&E), each with its own structure and function.
Besides its role during epidermal differentiation, it is revealed that LCE3 proteins, and in particular LCE3A, have an antimicrobial activity. Besides it’s comparable defensin like AMP function, LCE3 proteins are small, cysteine rich and cationic. This activity can be inhibited at high ionic strength.
Furthermore, LCE3 genes and proteins are also associated with rheumatoid arthritis. Atopic dermatitis and SLE. The monoclonal antibody targets all paralogues of the psoriasis-associated LCE3 proteins, with the highest affinity for LCE3B&E. The antibody is raised against the GGPSSEGG epitope.
- IHC-P: All tissues and skin equivalents were fixed for 4 hours in 4% buffered formalin, processed and embedded in paraffin. Sections (6 µm) were processed for immunohistochemistry and immunofluorescence analyses (Ref. 1).
Related products
Powered by BiozCalculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP Research
Bridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research - New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
